ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0862

Mixed Effects Regression Models for Estimated Glomerular Filtration Rate in Glomerular Diseases

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Gadde, Sri, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Banker, Margaret, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Smith, Abigail R., Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Background

Disease progression in non-diabetic glomerular diseases is traditionally modeled assuming linear decline in estimated glomerular filtration rate (eGFR), despite known non-linearity in a subset of patients.

Methods

Adults and children with MCD, FSGS, MN, and IgAN/V from the Cure Glomerulonephropathy Network (CureGN) with at least 2 eGFR measurements were included. Mixed-effects linear regression models with random intercepts and slopes were fitted, stratified by age, sex, APOL1 risk alleles, hypertensive status, and weight status. Potential improvement of model fit with the inclusion of a quadratic term was assessed using likelihood ratio tests.

Results

Among 2790 participants, 34% were pediatric, 43% were female, 27% and 35% were overweight and obese, respectively, and 44% were hypertensive. Overall eGFR decline was -1.3 ml/min/1.73m2 per year, and was slowest in MCD (-0.2 per year) and fastest in FSGS (-2.0 per year). eGFR decline was faster in overweight and obese participants (-1.6 and -1.4 versus –0.8 per year, respectively, p=0.02) and those with Stage 1 and 2 hypertension (-1.5 and -2.2 versus -0.7 per year, p<0.001). Participants with MCD, those under 12 years old at enrollment, and those with normal weight and normal or elevated blood pressure had statistically significant quadratic terms for time (range -0.5 to –0.12), indicating periods of initial stability and subsequent decline, on average (Figure). Among the subset with genetic testing, those with 2 APOL-1 risk alleles (121/1,959) had faster progression (-3.2 ml/min/1.73m2 per year) and a significant quadratic mean trajectory (beta = 0.42), indicating steep initial decline followed by stabilization.

Conclusion

These findings underscore that eGFR decline is not uniform across patients with glomerular diseases but varies by demographic, genetic, and health factors. Non-linear modeling of eGFR in certain subgroups may improve risk prediction.

Funding

  • NIDDK Support

Digital Object Identifier (DOI)